Impairment of alternative splice sites defining a novel gammaretroviral exon within gagmodifies the oncogenic properties of Akv murine leukemia virus

Table 2 Frequency and latency of induced tumors

Virus	FBL	DLBCL (progression from FBL)	*De novo*DLBCL#	PCT	SMZL	DLBCL (progression from SMZL)	SBL	PTLL	STL	Histiocytic sarcoma
Akv-wt	9/40 (23%)	13/40 (33%)	0/40 (0%)	13/40 (33%)	3/40 (8%)	0/40 (0%)	2/40 (5%)	0/40 (0%)	0/40 (0%)	0/40 (0%)
Akv-CD*	0/18 (0%)	7/18 (39%)	0/18 (0%)	1/18 (6%)	5/18 (28%)	1/18 (6%)	0/18 (0%)	0/18 (0%)	0/18 (0%)	4/18 (22%)
Akv-EH	1/17 (6%)	4/17 (24%)	6/17 (35%)	3/17 (18%)	0/17 (0%)	1/17 (6%)	0/17 (0%)	0/17 (0%)	1/17 (6%)	0/17 (0%)
Akv-CDH	1/14 (7%)	5/14 (36%)	0/14 (0%)	5/14 (36%)	0/14 (0%)	0/14 (0%)	0/14 (0%)	1/14 (7%)	0/14 (0%)	0/14 (0%)
Total	11/88 (13%)	29/88 (33%)	6/88 (7%)	22/88 (25%)	8/88 (9%)	2/88 (2%)	2/88 (2%)	1/88 (1%)	1/88 (1%)	4/88 (5%)
Av. latency period (days)	188 ± 30	198 ± 31	187 ± 43	180 ± 27	207 ± 20	174 ± 18	153 ± 12	107	146	211 ± 36

Abbreviations: FBL, follicular B cell lymphoma; DLBCL, diffuse large B cell lymphoma; PCT, plasmacytoma; SMZL, splenic marginal zone lymphoma; SBL, small B cell lymphoma; PTLL, precursor T cell lymphoblastic lymphoma; STL, small T-cell lymphoma.
# De novo DLBCL refers to Bethesda classification "DLBCL centroblastic"; however, to stress the parallel to human de novo lymphomas we use this term.
*In this group one of the 17 mice that developed tumors had two tumors, hence a total number of 18 tumors.

ISSN: 1742-4690